Skip to main content
. 2006 Feb 9;107(11):4466–4474. doi: 10.1182/blood-2005-08-3490

Table 1.

Determination of neutralizing titers of polyclonal Ig purified from sera of infected individuals and of neutralizing monoclonal IgG using HIV-1BaL

Neutralizing titer, μg/mL
Coculture
iMDDCs, purified at 99% iMDDCs, purified at 85% PBLs, purified at 15% PHA-stimulated PBMCs
Polyclonal IgG
    IgG no. 44 35 30 175 220
    IgG no. 8 40 30 250 155
    IgG no. 24 35 40 200 390
    IgG no. 23 60 45 400 600
    IgG no. 33 65 ND ND 265
    IgG no. 36 35 ND ND 350
    IgG no. 11 130 130
    IgG no. 3 350 195
    IgG control
Polyclonal IgA
    IgA no. 8 215 290 250 360
    IgA no. 6 320 200 385 260
    IgA no. 35
    IgA control
Monoclonal IgG
    IgG1 b12 1 3 15 25
    2F5 IgG1k 2 4 50 30
    447-52D IgG3 3 3 50 50
    2G12 IgG1k 1 0.5 ND 50
    4E10 IgG1 5 ND ND 50
Recombinant
    sCD4 5 7 10 10

Purified HIV-1BaL was preincubated with serial concentrations of polyclonal Ig purified from sera of HIV-1 patients or of neutralizing monoclonal IgG. Neutralizing titers that correspond to the concentration of Ig able to reduce the percentage of infected cells by 90% were determined for each cellular subset (purified iMDDCs, coculture of iMDDCs with 15% of PBLs, or PHA-stimulated PBMCs). Data are mean of 4 experiments performed with cells from at least 4 different donors.

— indicates no neutralizing activity detected at 800 μg/mL polyclonal Ig; ND, not determined.